Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Thrombosis Prophylaxis with Apixaban in Patients Treated with Asparaginase

Krishna Gundabolu, Vijaya R. Bhatt, Lynette M. Smith, Valerie K Shostrom, Lori J. Maness, Zaid S. Al-Kadhimi, Julie M. Vose, R. Gregory Bociek, Matthew A. Lunning, Avyakta Kallam, Christopher D'Angelo, Muhamed Baljevic, Apar K Ganti

Blood (2021) 138 (Supplement 1): 1069.

https://doi.org/10.1182/blood-2021-148945

Published: 2021

Journal Articles

Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes

Amulya Yellala, MBBS, Elizabeth R. Lyden, MS, Heather Nutsch, Avyakta Kallam, MD, Kai Fu, MD PhD, Timothy C. Greiner, MS, MD, Philip Bierman, MD, Matthew A. Lunning, DO, FACP, R. Gregory Bociek, MD, James O. Armitage, MD, Julie M. Vose, MD MBA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-142743

Published: 2020

Journal Articles

A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Matthew A. Lunning, DO, Philip Bierman, MD, R. Gregory Bociek, MD, James O. Armitage, MD, Peggy Heires, R.N., Maribeth Hohenstein, R.N, Susan Blumel, RN, Jonathan Tefft, B.A., Elizabeth R. Lyden, MS, Michael R Green, PhD, Julie M. Vose, MD MBA

Blood (2018) 132 (Supplement 1): 5390.

https://doi.org/10.1182/blood-2018-99-119765

Published: 2018

Journal Articles

Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Matthew A. Lunning, DO, Philip Bierman, MD, R. Gregory Bociek, MD, Marshall T. Schreeder, MD, Tanya Siddiqi, MD, Christopher R Flowers, MD MS, Jonathon B. Cohen, MD MS, Susan Blumel, RN, Kathy Cutter, RN, Emily K. Pauli, BMBS,PharmD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Julie M. Vose, MD MBA

Blood (2018) 132 (Supplement 1): 4197.

https://doi.org/10.1182/blood-2018-99-118917

Published: 2018

Journal Articles

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O’Connor, Neil Josephson, Yinghui Wang, Ranjana Advani

Blood (2018) 132 (1): 40–48.

https://doi.org/10.1182/blood-2017-11-815183

Published: 2018

Includes: Supplemental data

Journal Articles

Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Avyakta Kallam, MBBS, Jane Meza, PhD, Philip Bierman, MD, Matthew A. Lunning, DO, R. Gregory Bociek, MD, James Olen Armitage, MD, Julie M Vose, MD

Blood (2017) 130 (Supplement 1): 4039.

https://doi.org/10.1182/blood.V130.Suppl_1.4039.4039

Published: 2017

Journal Articles

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

Andrew M Evens, DO,MSc, Ranjana H. Advani, MD, Michelle A. Fanale, MD, Sonali M. Smith, MD, Irene Helenowski, PhD, Borko Jovanovic, PhD, R. Gregory Bociek, MD, Andreas Klein, MD, Jane N. Winter, MD, Leo I. Gordon, MD, Paul A. Hamlin, MD

Blood (2017) 130 (Supplement 1): 733.

https://doi.org/10.1182/blood.V130.Suppl_1.733.733

Published: 2017

Journal Articles

Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)

Jayadev Manikkam Umakanthan, MBBS, Lori J. Maness, MD, Jiangtao Luo, Avyakta Kallam, MBBS, James O. Armitage, MD, Philip Bierman, MD, Julie M. Vose, MD, R. Gregory Bociek, MD, Matthew Lunning, DO, Krishna Gundabolu, MD, Vijaya R. Bhatt, MD

Blood (2016) 128 (22): 5154.

https://doi.org/10.1182/blood.V128.22.5154.5154

Published: 2016

Journal Articles

Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

Matthew Lunning, DO, Philip J Bierman, MD, R. Gregory Bociek, MD, Marshall T. Schreeder, MD, Susan Blumel, RN, BSN, Kathy Cutter, RN, BSN, Emily K. Pauli, BMBS, PharmD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Julie M Vose, MD

Blood (2016) 128 (22): 4197.

https://doi.org/10.1182/blood.V128.22.4197.4197

Published: 2016

Journal Articles

Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL

Ashima Shukla, Karan Rai, Vipul Shukla, Nagendra K. Chaturvedi, R. Gregory Bociek, Samuel J. Pirruccello, Hamid Band, Runqing Lu, Shantaram S. Joshi

Blood (2016) 127 (19): 2310–2321.

https://doi.org/10.1182/blood-2015-09-669317

Published: 2016

Includes: Supplemental data

Journal Articles

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)

Anas Younes, MD, Gilles Salles, Giovanni Martinelli, R. Gregory Bociek, MD, Dolores Caballero Barrigon, MD, Eva Gonzalez Barca, Mehmet Turgut, MD PhD, John F. Gerecitano, MD, Fabian Herbst, Lisa Williams, Nabanita Mukherjee, Ranjana Tavorath, Won Seog Kim, MD PhD

Blood (2015) 126 (23): 1493.

https://doi.org/10.1182/blood.V126.23.1493.1493

Published: 2015

Journal Articles

Tolerability and Efficacy of Treatments in Elderly Patients with Hodgkin Lymphoma: A Report from the Nebraska Lymphoma Study Group

Roberto A. Ferro, MD, Vijaya R. Bhatt, MD, Martin Bast, BS, Lynette Smith, MS, R. Gregory Bociek, MD, Matthew A. Lunning, DO, Philip J Bierman, MD, Julie M. Vose, MD, James O. Armitage, MD

Blood (2015) 126 (23): 1504.

https://doi.org/10.1182/blood.V126.23.1504.1504

Published: 2015

Journal Articles

National Trend in Splenectomy for Splenic Marginal Zone Lymphoma (SMZL): An Analysis of Surveillance, Epidemiology and End Results (SEER) Database

Smith Giri, MBBS, Vijaya R. Bhatt, MD, Ranjan Pathak, MD, R. Gregory Bociek, MD, James O. Armitage, MD

Blood (2015) 126 (23): 5630.

https://doi.org/10.1182/blood.V126.23.5630.5630

Published: 2015

Journal Articles

Use of Low Molecular Weight Heparin (LMWH) in Thrombocytopenic Patients with Hematologic Malignancy-Associated Venous Thromboembolism (VTE)

Nabin Khanal, MBBS, R. Gregory Bociek, MD, Baojiang Chen, PhD, Julie M. Vose, MD, James O. Armitage, MD, Philip J Bierman, MD, Lori J. Maness, MD, Matthew A. Lunning, DO, Krishna Gundabolu, MD, Vijaya R. Bhatt, MD

Blood (2015) 126 (23): 3482.

https://doi.org/10.1182/blood.V126.23.3482.3482

Published: 2015

Journal Articles

Clinicopathologic Features, Management and Outcomes of Blastoid Variant (BV) of Mantle Cell Lymphoma (MCL): A Nebraska Lymphoma Study Group (NLSG) Experience

Vijaya R. Bhatt, MBBS, Fausto R. Loberiza, MD MS, James O. Armitage, MD, Timothy C. Greiner, MS, MD, Martin Bast, BS, Matthew A. Lunning, DO, Philip Bierman, MD, Julie M. Vose, MD MBA, R. Gregory Bociek, MD MSc.

Blood (2014) 124 (21): 2971.

https://doi.org/10.1182/blood.V124.21.2971.2971

Published: 2014

Journal Articles

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Ann LaCasce, MD, R. Gregory Bociek, MD, Jeffrey Matous, MD, Ahmed Sawas, MD, Paolo Caimi, MD, Stephen M. Ansell, MD PhD, Miguel Islas-Ohlmayer, MD, Eric Cheung, MD, Edward Agura, MD, Caroline Behler, MD, Howland Crosswell, MD, Julie M. Vose, MD MBA, Neil Josephson, MD, Ranjana Advani, MD

Blood (2014) 124 (21): 293.

https://doi.org/10.1182/blood.V124.21.293.293

Published: 2014

Journal Articles

Restrospective Review of Incidence, Complications and Management of Tumor Lysis Syndrome in High Risk Patients with Hematologic Malignancies

Devon M Greer, PharmD, Jairam Krishnamurthy, MD, Susanne Liewer, PharmD, Mojtaba Akhtari, MD, Lori J. Maness, MD, R. Gregory Bociek, MD

Blood (2014) 124 (21): 2621.

https://doi.org/10.1182/blood.V124.21.2621.2621

Published: 2014

Journal Articles

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma

Anas Younes, Gilles Salles, MDPhD, R. Gregory Bociek, MD, Giovanni Martinelli, Dolores Caballero, Eva González Barca, Nabanita Mukherjee, Lisa Williams, Fabian Herbst, Ranjana Tavorath, Won Seog Kim

Blood (2014) 124 (21): 1718.

https://doi.org/10.1182/blood.V124.21.1718.1718

Published: 2014

Journal Articles

Trend Analysis of Clinical Outcomes in Hodgkin Lymphoma over the Last Three Decades: Report from the Nebraska Lymphoma Study Group

Kailash Mosalpuria, MD MPH, Fausto R Loberiza, MD MS, R. Gregory Bociek, MD, Matthew A. Lunning, DO, Apar Kishor Ganti, MD, James Olen Armitage, MD, Julie M. Vose, MD, Philip Bierman, MD

Blood (2014) 124 (21): 1284.

https://doi.org/10.1182/blood.V124.21.1284.1284

Published: 2014

Journal Articles

Utility Of Pre-Chemotherapy Echocardiograms

John Allen Steuter, MD/Cardiology Fellow, Philip Bierman, MD, R. Gregory Bociek, MD, Martin Bast, BS

Blood (2013) 122 (21): 2950.

https://doi.org/10.1182/blood.V122.21.2950.2950

Published: 2013

NARROW

Thrombosis Prophylaxis with Apixaban in Patients Treated with Asparaginase

Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes

A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)

Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)

Tolerability and Efficacy of Treatments in Elderly Patients with Hodgkin Lymphoma: A Report from the Nebraska Lymphoma Study Group

National Trend in Splenectomy for Splenic Marginal Zone Lymphoma (SMZL): An Analysis of Surveillance, Epidemiology and End Results (SEER) Database

Use of Low Molecular Weight Heparin (LMWH) in Thrombocytopenic Patients with Hematologic Malignancy-Associated Venous Thromboembolism (VTE)

Clinicopathologic Features, Management and Outcomes of Blastoid Variant (BV) of Mantle Cell Lymphoma (MCL): A Nebraska Lymphoma Study Group (NLSG) Experience

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Restrospective Review of Incidence, Complications and Management of Tumor Lysis Syndrome in High Risk Patients with Hematologic Malignancies

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma

Trend Analysis of Clinical Outcomes in Hodgkin Lymphoma over the Last Three Decades: Report from the Nebraska Lymphoma Study Group

Utility Of Pre-Chemotherapy Echocardiograms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only